• Molecular NameNizatidine
  • SynonymNA
  • Weight331.465
  • Drugbank_IDDB00585
  • ACS_NO76963-41-2
  • Show 3D model
  • LogP (experiment)-0.2
  • LogP (predicted, AB/LogP v2.0)-0.04
  • pka2.1, 6.8
  • LogD (pH=7, predicted)-0.15
  • Solubility (experiment)21.5 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)0.48
  • LogSw (predicted, AB/LogsW2.0)14.91
  • Sw (mg/ml) (predicted, ACD/Labs)1000.0
  • No.of HBond Donors2
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds10
  • TPSA142.56
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA histamine H2-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).
  • Absorption_value95.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability70.0
  • Protein binding35.0
  • Volume of distribution (VD)1.2 to 1.6 L/kg (single 150 mg dose); 1.1 to 1.9 L/kg (multiple doses).
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmOrally administered nizatidine undergoes minimal metabolism on first pass through the liver.Nizatidine is oxidized in the liver to 18N-desmethylnizatidine, nizatidine 18N-oxide, and nizatidine 10S-sulfoxide.Of these metabolites, only N-desmethylnizatidine has histamine H2-receptor blocking activity.
  • Half life1.3~1.6 h (prolonged in renal impairment)
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include cholinergic-type effects including lacrimation, salivation, emesis, miosis, and diarrhea.
  • LD50 (rat)LD50=301 mg/kg
  • LD50 (mouse)N/A